Floatz logo

Tazobactam

Pseudomonas Aeruginosa

Sunshine Coast Hospital and Health ServiceSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Pseudomonas Aeruginosa cohort.

Asset / SponsorPhaseRating
Ap-Pa02
Armata Pharmaceuticals, Inc.
Phase 2BB
Aztreonam Lysine
Gilead Sciences
Phase 3BB
CEFTOLOZANE
Sunshine Coast Hospital and Health Service
Phase 4BB
Piperacillin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
bx004-a
BiomX Ltd
Phase 2BB

View all 12 →

Same molecule, other indications

Tazobactam is also rated in:

Pseudomonas infectionDormant
BB
Indicative ·
69 / 100
View asset →
bronchiectasisDormant
BB
Indicative ·
65 / 100
View asset →
burkholderia infectious diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →